Neos Therapeutics Inc., is a specialty pharmaceutical company focused on the development and manufacture of FDA approved drug products that utilize the Company's proprietary and patented delivery technologies. The Neos drug products are being developed using the Dynamic Time Release Suspension® (DTRS®) and Rapidly Disintegrating Ionic Masking (RDIM) technologies that deliver controlled release (CR) small molecule active pharmaceutical ingredients (APIs) in either liquid or orally disintegrating tablet (ODT) dosage forms. By utilizing APIs that are already FDA-approved, Neos can reduce development and regulatory risk and efficiently advance targeted proprietary Rx products through the FDA's New Drug Application (NDA) approval process.
Date | Amount | Type | Investors | Valuation |
---|---|---|---|---|
04/23/14 | $18,000,000 | Series C |
CAC CMEA Capital Crabtree Partners Delaware Street Capital | undisclosed |